SEPNNasdaq

Septerna, Inc.

Healthcare·Endocrinology·Phase 1·South San Francisco, CA, United States
Endocrinology

Septerna, Inc. (SEPN): 3 pipeline candidates · ~40 mo cash runway · 2 clinical trials. Updated within the last hour.

5.8/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway10.0

39.8 months

Financial Health9.2

D/E 0.51 · 0% dilution

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider Signal0.0

0 buys · 11 sells (180d)

A transparent, data-derived signal for Septerna, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$1.6B

Cash

$71.6M

Quarterly Burn

$25.6M

Runway

39.8 mo

Revenue

$26.5M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Oct 2029
Today~44 mo out
Catalyst within runway

Pipeline (3 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

123

Total value held

$1.07B

HolderSharesValue
ra capital management, l.p.6,995,858$168.1M
trv gp v, llc6,215,591$149.4M
driehaus capital management llc4,395,572$105.6M
trv gp vi, llc4,211,659$101.2M
samsara biocapital, llc3,149,128$75.7M
goldman sachs group inc2,906,427$69.8M
vanguard capital management llc2,393,924$57.5M
blackrock, inc.1,822,174$43.8M
janus henderson group plc1,781,508$42.7M
bvf inc/il1,353,249$32.5M

Showing top 10 of 123 institutional holders of Septerna, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

2 clinical trials·CEO: Dr. Jeffrey T. Finer M.D., Ph.D.

Frequently asked questions

How many drug candidates are in Septerna, Inc.'s pipeline?

Septerna, Inc. (SEPN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Septerna, Inc.'s lead drug candidate?

Septerna, Inc.'s most advanced tracked candidate is pth1r agonist (Preclinical) for hypoparathyroidism.

What is Septerna, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Septerna, Inc. has approximately 39.8 months of cash runway.

What is Septerna, Inc.'s market capitalization?

Septerna, Inc.'s market capitalization is approximately $1.6B.

Who is the CEO of Septerna, Inc.?

Dr. Jeffrey T. Finer M.D., Ph.D. is the chief executive officer of Septerna, Inc. (SEPN).

Get the full picture on Septerna, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.